Akero Therapeutics, Inc. (NASDAQ:AKRO) Receives $82.50 Consensus Target Price from Analysts

Shares of Akero Therapeutics, Inc. (NASDAQ:AKROGet Free Report) have been assigned an average recommendation of “Buy” from the six research firms that are currently covering the company, Marketbeat.com reports. Six analysts have rated the stock with a buy rating. The average 12-month target price among brokers that have covered the stock in the last year is $82.50.

A number of equities research analysts have weighed in on AKRO shares. Bank of America lifted their price target on shares of Akero Therapeutics from $63.00 to $64.00 and gave the stock a “buy” rating in a research note on Tuesday, May 27th. Morgan Stanley reiterated an “overweight” rating on shares of Akero Therapeutics in a research report on Sunday, March 2nd. Citigroup lowered their target price on shares of Akero Therapeutics from $80.00 to $78.00 and set a “buy” rating on the stock in a research note on Tuesday, May 13th. Finally, HC Wainwright increased their price target on shares of Akero Therapeutics from $72.00 to $75.00 and gave the stock a “buy” rating in a research report on Monday, March 3rd.

Get Our Latest Research Report on AKRO

Insider Activity

In other news, Director G. Walmsley Graham acquired 50,000 shares of the company’s stock in a transaction dated Thursday, March 27th. The stock was bought at an average price of $43.55 per share, with a total value of $2,177,500.00. Following the completion of the acquisition, the director now owns 1,200,000 shares in the company, valued at approximately $52,260,000. This represents a 4.35% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Timothy Rolph sold 6,250 shares of the stock in a transaction that occurred on Monday, April 7th. The stock was sold at an average price of $35.88, for a total value of $224,250.00. Following the sale, the insider now owns 169,721 shares in the company, valued at approximately $6,089,589.48. This trade represents a 3.55% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 232,979 shares of company stock worth $10,935,650. Corporate insiders own 7.07% of the company’s stock.

Institutional Trading of Akero Therapeutics

Large investors have recently made changes to their positions in the business. Voya Investment Management LLC raised its holdings in shares of Akero Therapeutics by 302.9% in the first quarter. Voya Investment Management LLC now owns 82,471 shares of the company’s stock valued at $3,338,000 after buying an additional 62,000 shares during the last quarter. Rhumbline Advisers increased its position in Akero Therapeutics by 4.7% in the 1st quarter. Rhumbline Advisers now owns 110,687 shares of the company’s stock valued at $4,481,000 after acquiring an additional 5,001 shares in the last quarter. Strs Ohio bought a new position in shares of Akero Therapeutics in the first quarter worth about $510,000. Intech Investment Management LLC raised its stake in shares of Akero Therapeutics by 54.4% in the first quarter. Intech Investment Management LLC now owns 58,522 shares of the company’s stock worth $2,369,000 after acquiring an additional 20,620 shares during the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in shares of Akero Therapeutics by 53.8% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 109,909 shares of the company’s stock worth $4,449,000 after purchasing an additional 38,458 shares in the last quarter.

Akero Therapeutics Stock Down 0.3%

AKRO stock opened at $54.03 on Thursday. Akero Therapeutics has a twelve month low of $21.02 and a twelve month high of $58.40. The company has a quick ratio of 16.80, a current ratio of 16.80 and a debt-to-equity ratio of 0.03. The company has a market cap of $4.31 billion, a PE ratio of -27.71 and a beta of -0.16. The business’s 50-day simple moving average is $46.21 and its 200 day simple moving average is $41.41.

Akero Therapeutics (NASDAQ:AKROGet Free Report) last announced its quarterly earnings data on Monday, May 12th. The company reported $0.90 EPS for the quarter, topping analysts’ consensus estimates of ($1.01) by $1.91. On average, research analysts anticipate that Akero Therapeutics will post -3.99 earnings per share for the current year.

About Akero Therapeutics

(Get Free Report

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.

Recommended Stories

Analyst Recommendations for Akero Therapeutics (NASDAQ:AKRO)

Receive News & Ratings for Akero Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akero Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.